Head-to-head · WeighScore
Iron Med RX vs Zealthy
The verdict
Iron Med RX takes it — 54.8/100 to 46.7/100.
Iron Med RX grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Iron Med RX (IRON RX Telehealth) is a Dallas-based online weight-loss provider offering compounded GLP-1 with licensed-provider oversight and home delivery.
We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.
Factor by factor
The same six graded dimensions, side by side. See the methodology.
The numbers
| Metric | Iron Med RX | Zealthy |
|---|---|---|
| WeighScore | 54.8/100 | 46.7/100 |
| Grade | C | C |
| Scorecard rank | #453 | #496 |
| Semaglutide | Not disclosed | $286/mo (starting dose, plus a separate fee, compounded) |
| Tirzepatide | Not disclosed | $351/mo (starting dose, plus a separate fee, compounded) |
| Coverage | Coverage not published | 34 states |
| Brand-name access | Compounded only | Compounded only |
| Oral / sublingual | Yes | Injection only |
Graded #453 · C
Strengths
- Unusually broad GLP-1 lineup — compounded semaglutide and tirzepatide in both oral tablets and injection, plus microdosing and longevity add-ons
- Online process with licensed-provider oversight, virtual consults, progress tracking and home delivery
- Oral tablet options for people who would rather not inject
Where it loses points
- Prices are not shown publicly — you only see costs after creating an account, so you cannot compare value upfront
- Labels its oral semaglutide 'research-grade' — wording usually tied to research/non-prescription peptides; confirm it is prescribed for human use
- Does not name its compounding pharmacy or list the states it serves; the listed address is a private mailbox (PMB), not a clinic
- Compounded GLP-1 only — no brand-name or insurance options; small, lightly documented operation
Graded #496 · C
Strengths
- Serves 34 states — meaningful nationwide footprint
- Asynchronous model removes friction for patients who don't want a video visit
- Independent licensed prescribers retain full clinical authority
Where it loses points
- Active Novo Nordisk false-advertising lawsuit alleging trademark infringement and marketing compounded drugs as FDA-approved alternatives
- Active DOJ/FTC enforcement alleging undisclosed subscription terms, locked cancellation, and unauthorized health-data sharing
- Founder previously ran Cerebral, which settled with the FTC in 2024 over similar deceptive practices
- Recently rebranded to Gronk Inc. amid active enforcement
- FDA issued this company a warning letter dated 1 September 2025; the letter is public in FDA's warning-letter database
Also worth a look
Neither is our top-graded pick — CoreAge Rx leads the scorecard
Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.
Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.